Biogen Idec Inc $343.49

up +0.45


2/9/2014 11:00 AM  |  NASDAQ : BIIB  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get BIIB Trend Analysis - it has outperformed the S&P 500 by 38%

Partner Headlines

  1. Biogen: Moving From Collaboration To Innovation

    IBD
  2. Economic Data Fuel Another All-Time High For S&P 500

    IBD
  3. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD
  4. Biogen, Celgene In Buy Range; LinkedIn Coming Back

    IBD
  5. Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs

    IBD
  6. Majority Of IBD 50 Firms Strong On Sponsorship

    IBD
  7. Biogen's buy rating reaffirmed

    IBD
  8. UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy Approval

    Benzinga
  9. Perrigo Regains Some Lost Ground On Fiscal Q4 Beat

    IBD
  10. Perrigo Q4 Beats Estimates, But Guidance Misses

    IBD
  11. Tech, Health Care Lead Q2 Earnings Beats

    IBD
  12. #PreMarket Primer: Friday, August 8: U.S. To Begin Airstrikes In Iraq

    Benzinga
  13. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  14. Why Investors Should Closely Watch Celgene

    Benzinga
  15. Biotech Gets A Lift On Popular Drug, Strong Pipeline

    IBD
  16. Ken Fisher's Top Increaes of the Second Quarter

    GuruFocus
  17. Ken Fisher's Top Increases of the Second Quarter

    GuruFocus
  18. Chipotle, Facebook Rally On Upside Earnings Surprise

    IBD
  19. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  20. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD
  21. Biogen, Gilead Profits Soar

    IBD
  22. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD
  23. S&P 500 Posts New High; Biotechs, Airlines, Builders Up

    IBD
  24. IPO Stock Watch: Biotechs Are Half Of July Calendar

    IBD
  25. Vertex Is Poised For An Earnings Breakout

    Benzinga
  26. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential Buyout ...

    Benzinga
  27. S&P 500 Flirts With High; Breadth Missing On Nasdaq

    IBD
  28. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga
  29. S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade

    IBD
  30. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD
  31. Apple, Microsoft Lead Nasdaq Higher; Dow Falters

    IBD
  32. Markets Mixed; PepsiCo Q2 Earnings Beat Street View

    Benzinga
  33. Stocks: Mixed Open, Mixed Trade; Delta, Broadcom, Biogen Buck Up

    IBD
  34. Morning Market Movers

    Benzinga
  35. UPDATE: Biogen Idec Posts Stronger-Than-Expected Q2 Results, Shares Surge

    Benzinga
  36. Stock Futures Up, But Wobbly; Boeing, Apple, Biogen Rising

    IBD
  37. Benzinga's Top #PreMarket Gainers

    Benzinga
  38. Earnings Scheduled For July 23, 2014

    Benzinga
  39. Stocks Rise; Apple, Microsoft Steady In Post-Session

    IBD
  40. Alexion, 3 Other Top Biotechs Reporting Earnings

    IBD
  41. Stocks Climb In Solid Trade; Chipotle Gaps Up, Breaks Out

    IBD
  42. Oil Dominates; Keurig, Constellation Near Buy Points

    IBD
  43. IBD 50 Ends Week Lower But Skyworks Soars

    IBD
  44. Biogen Shares Rebound As Street Has A Change Of Heart

    IBD
  45. Facebook, Gilead Headline IBD 50's Top 5 Earnings

    IBD
  46. IBD 50 Ends Week Lower But Skyworks Soars

    IBD
  47. Biotech Enters Reporting Season With Large Caps Central To Sector Performance

    Benzinga
  48. Baxter Q2 Earnings Beat Estimates, But Guidance Soft

    IBD
  49. IBD Big Cap 20 Leaders Hold Up Well Despite Shaky Market

    IBD
  50. Biogen's Profit Rolls Amid Recent Drug Launches

    IBD
Trading Center